Skip to main content
Premium Trial:

Request an Annual Quote

Insilico, Champions Expand Collaboration around TumorGrafts Technology

NEW YORK (GenomeWeb) – Bioinformatics firm Insilico Medicine and Champions Oncology have announced they will expand an existing collaboration and work together to validate preliminary findings showing that molecular signatures of patients' tumor grafts in mice resemble the signatures in human patients before and after treatment.

As part of this research, Insilico has been using Champion's TumorGrafts – a technology that enables researchers to engraft a piece of a patient's tumor onto immune-deficient mice and assess whether a particular treatment strategy is likely to be effective against the patient's disease. The procedure has shown to be a viable strategy for predicting response with single-agent and combination chemotherapy regimes, as well as targeted biologics.

In this latest collaboration, Insilico will analyze gene expression data from Champions' tumor grafts before and after treatment, and compare them to signal pathway activation state changes in human cancer patients.

"This research collaboration may pave the way for a comprehensive drug discovery and development pipeline, where drugs and drug candidates may be selected and prioritized using in silico approaches and tested in human tissues engrafted into Champions Oncology mice or other animal models," Qingsong Zhu, Insilico's chief operating officer, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.